Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 5Phase NA 1Phase 2/3 1

Status

Recruiting 104Active not recruiting 97Completed 37Not yet recruiting 23Terminated 22Withdrawn 14Unknown 7Suspended 5Enrolling by invitation 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 2Tumor-Agnostic 1Lymphoid 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Glioblastoma 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 5Nivolumab 4Capecitabine 4Vincristine 3Radiosurgery 3Paclitaxel 3Irinotecan 3Fluorouracil 3Everolimus 3Docetaxel 3Dexamethasone 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3trifluridine tipiracil drug combination 2spartalizumab 2pembrolizumab 2lenvatinib 2daratumumab 2Taxes 2Radiation 2Prednisone 2Pemetrexed 2Oxaliplatin 2Mitoxantrone 2Leucovorin 2Injections 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Suspended × Biopsy × Clear all
NCT06325683 2026-05-26

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Suspended
184 enrolled
CNS

Glioblastoma

NCT05554380 2026-05-22

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03375307 2026-05-13

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03575611 2026-04-15

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

M.D. Anderson Cancer Center

Phase 2 Suspended
123 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT06575686 2026-01-21

Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

City of Hope Medical Center

Phase 2 Suspended
33 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡